Sleep-disordered breathing in chronic heart failure is highly variable when measured remotely using a novel non-contact biomotion sensor Sleep-disordered breathing (SDB) is common in heart failure (HF) and considered a potential risk factor for, or a marker of, disease progression. 1 -3 The diagnosis of SDB is traditionally made during a single polysomnographic study (PSG) which measures the number of apnoeas/hypopnoeas/h and categorizes them as obstructive, central, or mixed. There is substantial night to night variability in the severity of SDB measured by PSG which is less, but still present, in home PSG. In HF, the effects of postural fluid shifts 4 and changes in the HF syndrome over time 5 may increase the variability of SDB. The lack of technology to measure SDB over prolonged periods has prevented longer term assessment of SDB in HF.
We used a non-contact biomotion sensor (SleepMinder™; SM ResMed Sensor Technologies, Dublin, Ireland) previously validated against PSG measured apnoea/hypopnoea index (AHI SM ) in HF 6 The two sites enrolled patients of similar age (mean ± SD: Dublin 75 ± 9 years, London 77 ± 9 years), gender (69% male vs. 72%), left ventricular ejection fraction (37 ± 13% vs. 38 ± 13%) and reduced vs. preserved left ventricular systolic function (69% vs. 67%). Dublin patients had a higher prevalence of hypertension (57% vs. 32%, P = 0.01), atrial fibrillation (57% vs. 28%, P = 0.01), BNP levels (170 ± 179 pg/ml, 135 ± 89, P = 0.008), a lower incidence of cardiac resynchronization therapy (5% vs. 40%, P < 0.001) but more episodes of HF decompensation (57% vs. 26%, P < 0.005).
Analysis of the total study period or global analysis identified three groups with similar patterns at the two sites Table 1 ). The no-SDB group (44% with total AHI SM <15/h) included patients who had this consistently but also included others with transient blocks of AHI SM >15/h (Figure 1a) . Patients with paroxysmal SDB (38%) showed four distinct patterns of transitions between states of SDB and no-SDB over prolonged periods (Figure 1b) . Although there were periods of relatively stable AHI SM this changed quite suddenly in many and was persistently unstable in others.
Patients with chronic or persistent SDB (18%) showed an AHI SM ≥15/h across the whole data collection period (Figure 1c ). Within this group some patients were relatively stable with an AHI SM ≥15/h for the whole period whereas others consistently showed fluctuations in the AHI SM (up or down) across consecutive blocks and 58% having at least one block of AHI SM ≥15/h at some point. Overall, while a minority (30%) had an average AHI SM >15/h during the total period of remote monitoring, most patients (58%) had at least one 2-week period of clinically significant SDB while monitored continuously.
Using SM technology to remotely monitor the AHI over prolonged periods in HF patients showed that our current understanding of SDB in HF patients is overly simplistic. There is substantial variation in the presence and severity of SDB despite optimal guidelinebased management of HF in two specialist HF clinics. The variability in SDB could not be detected by a single or several single PSG studies. This technology has the potential to identify short-and long-term changes in SDB relatively rapidly for potentially earlier 
